X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Sumitomo announces Partnership with Bukwang on its Atypical Antipsychotic Agent Lurasidone for Korea

Yuvraj_pawp by Yuvraj_pawp
7th April 2017
in Research & Development

 

Sumitomo Dainippon Pharma Co., Ltd. announced that the Company has concluded a license agreement with Bukwang Pharmaceutical Co., Ltd. relating to the development,sales and so on in Korea of lurasidone hydrochloride , an atypical antipsychotic agent, originally created by Sumitomo Dainippon Pharma.

Under the terms of the agreement, Bukwang will have the exclusive license of lurasidone to develop, sell and so on in Korea and Sumitomo Dainippon Pharma will receive upfront, launch milestone and sales milestone payments from Bukwang and supply lurasidone bulk tablets to Bukwang. Bukwang will conduct the bridging phase 3 study of lurasidone for schizophrenia in Korea.Sumitomo Dainippon Pharma plans to continue expanding the global presence of lurasidone as a treatment option for patients with schizophrenia and bipolar disorder.


About Bukwang Pharmaceutical Co., Ltd.:

Bukwang is Korean pharmaceutical company, founded in 1960, its employment is approximately 600 and its total sales in FY2015 amounted to approximately 14 billion yen.Bukwang has made available LONASEN® (blonanserin), an atypical antipsychotic agent, licensed from Sumitomo Dainippon Pharma since October 2010.


About Lurasidone:

Lurasidone is an atypical antipsychotic created originally by Sumitomo Dainippon Pharma, characterized by a unique chemical structure and an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, lurasidone is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine H1 or muscarinic M1 receptors.


Lurasidone has been available for the treatment of schizophrenia in the United States since 2011,in Canada since 2012, in Switzerland since 2013, in Denmark, Norway and the U.K. since 2014, in the Netherlands, Finland and Australia since 2015, and in Sweden since 2016. Sumitomo Dainippon Pharma is conducting Phase 3 studies with a view to obtaining approvals of lurasidone for the treatment of schizophrenia, bipolar I depression and bipolar maintenance in Japan and 
submitted the New Drug Application for the treatment of schizophrenia in China. Similar efforts are ongoing in collaboration with Daiichi Sankyo Company, Limited for four Latin American countries,with Standard Chem. & Pharm. Co., Ltd. for Taiwan, with DKSH (Thailand) Limited for Thailand,Singapore and Hong Kong, with Servier Laboratories Australia Pty Ltd. for Australia and with NewBridge Pharmaceuticals Limited for the six countries of the Gulf including Saudi Arabia and
Kuwait.


Contact:

Public Relations/Investor Relations
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka);
+81-3-5159-3300 (Tokyo)

Previous Post

Medidata Wins Informa CARE Award for “Clinical Trial Partnership of the Year”

Next Post

NuMedii, Inc. Announces New Partnership To Discover New Treatments For Idiopathic Pulmonary Fibrosis

Related Posts

Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Insights

Advancing Asia-Pacific Healthcare & Biopharma Innovation

7th March 2025
Insights

Generative AI in Pharma: Opportunities & Challenges

7th March 2025
Drug Development

Global Biopharma Market to Hit $566B by 2032

7th March 2025
Clario joins forces with Mobilise-D to advance Digital Mobility Outcomes in clinical trials
News

Detect-ION and Moffitt Cancer Center Collaborate to Revolutionize Lung Cancer Early Detection

19th August 2024
Next Post

Valeo Pharma and Zambon form partnership for Parkinsons Disease Treatment Xadago

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In